Buparlisib, a PI3K Inhibitor, Demonstrates Acceptable Tolerability and Preliminary Activity in a Phase I Trial of Patients with Advanced Leukemias

This article is protected by copyright. All rights reserved.

Source: American Journal of Hematology - September 26, 2016 Category: Hematology Authors: Brittany Knick Ragon, Hagop Kantarjian, Elias Jabbour, Farhad Ravandi, Jorge Cortes, Gautam Borthakur, LaKiesha DeBose, Zhihong Zeng, Heather Schneider, Naveen Pemmaraju, Guillermo Garcia ‐Manero, Steven Kornblau, William Wierda, Jan Burger, Courtney D. Tags: Research Article Source Type: research